Cargando…

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma

INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakajima, Nobuyuki, Kano, Tatsuo, Oda, Kazuya, Uchida, Takato, Otaki, Tatsuya, Nagao, Kentaro, Shimizu, Yuki, Kawakami, Masayoshi, Kim, Hakushi, Nitta, Masahiro, Hasegawa, Masanori, Kawamura, Yoshiaki, Miyajima, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469856/
https://www.ncbi.nlm.nih.gov/pubmed/32914080
http://dx.doi.org/10.1002/iju5.12195
_version_ 1783578479858548736
author Nakajima, Nobuyuki
Kano, Tatsuo
Oda, Kazuya
Uchida, Takato
Otaki, Tatsuya
Nagao, Kentaro
Shimizu, Yuki
Kawakami, Masayoshi
Kim, Hakushi
Nitta, Masahiro
Hasegawa, Masanori
Kawamura, Yoshiaki
Miyajima, Akira
author_facet Nakajima, Nobuyuki
Kano, Tatsuo
Oda, Kazuya
Uchida, Takato
Otaki, Tatsuya
Nagao, Kentaro
Shimizu, Yuki
Kawakami, Masayoshi
Kim, Hakushi
Nitta, Masahiro
Hasegawa, Masanori
Kawamura, Yoshiaki
Miyajima, Akira
author_sort Nakajima, Nobuyuki
collection PubMed
description INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT1bN0M0). Seventeen years postoperatively, recurrence in the left lung hilum was observed. Despite administration of three molecular target drugs, all treatments were terminated due to adverse events. Nivolumab was initiated in December 2016. In August 2017, subcutaneous and lung metastases were observed. Moreover in January 2018, right renal metastasis was noted. After 22 cycles of nivolumab treatment, metastasis in the iliac bone was observed, and the patient was subjected to conventional palliative external beam radiation therapy. Five months after radiotherapy, there was significant reduction in multiple metastases. Here, we reported the case presenting with possible abscopal effect. CONCLUSION: Radiotherapy combined with immune checkpoint inhibitors may induce systemic effects against metastatic renal carcinoma.
format Online
Article
Text
id pubmed-7469856
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74698562020-09-09 Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma Nakajima, Nobuyuki Kano, Tatsuo Oda, Kazuya Uchida, Takato Otaki, Tatsuya Nagao, Kentaro Shimizu, Yuki Kawakami, Masayoshi Kim, Hakushi Nitta, Masahiro Hasegawa, Masanori Kawamura, Yoshiaki Miyajima, Akira IJU Case Rep Case Reports INTRODUCTION: Renal cell carcinoma has been considered radioresistant. Recently, several studies have reported the efficacy of combination therapy using radiotherapy and immune checkpoint inhibitors. CASE PRESENTATION: In 1999, a 56‐year‐old woman underwent left nephrectomy (clear cell carcinoma, pT1bN0M0). Seventeen years postoperatively, recurrence in the left lung hilum was observed. Despite administration of three molecular target drugs, all treatments were terminated due to adverse events. Nivolumab was initiated in December 2016. In August 2017, subcutaneous and lung metastases were observed. Moreover in January 2018, right renal metastasis was noted. After 22 cycles of nivolumab treatment, metastasis in the iliac bone was observed, and the patient was subjected to conventional palliative external beam radiation therapy. Five months after radiotherapy, there was significant reduction in multiple metastases. Here, we reported the case presenting with possible abscopal effect. CONCLUSION: Radiotherapy combined with immune checkpoint inhibitors may induce systemic effects against metastatic renal carcinoma. John Wiley and Sons Inc. 2020-07-07 /pmc/articles/PMC7469856/ /pubmed/32914080 http://dx.doi.org/10.1002/iju5.12195 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nakajima, Nobuyuki
Kano, Tatsuo
Oda, Kazuya
Uchida, Takato
Otaki, Tatsuya
Nagao, Kentaro
Shimizu, Yuki
Kawakami, Masayoshi
Kim, Hakushi
Nitta, Masahiro
Hasegawa, Masanori
Kawamura, Yoshiaki
Miyajima, Akira
Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title_full Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title_fullStr Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title_full_unstemmed Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title_short Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
title_sort possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469856/
https://www.ncbi.nlm.nih.gov/pubmed/32914080
http://dx.doi.org/10.1002/iju5.12195
work_keys_str_mv AT nakajimanobuyuki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT kanotatsuo possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT odakazuya possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT uchidatakato possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT otakitatsuya possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT nagaokentaro possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT shimizuyuki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT kawakamimasayoshi possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT kimhakushi possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT nittamasahiro possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT hasegawamasanori possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT kawamurayoshiaki possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma
AT miyajimaakira possibleabscopaleffectafterdiscontinuationofnivolumabinmetastaticrenalcellcarcinoma